OBSERVATIONS UPON THE EXPERIMENTAL AND CLINICAL USE OF SULFAPYRIDINE. II. THE TREATMENT OF PNEUMOCOCCAL PNEUMONIA WITH SULFAPYRIDINE
Authors: Perrin H. Long, W. Barry Wood
Journal: Annals of Internal Medicine (1939)

Article1 September 1939OBSERVATIONS UPON THE EXPERIMENTAL AND CLINICAL USE OF SULFAPYRIDINE. II. THE TREATMENT OF PNEUMOCOCCAL PNEUMONIA WITH SULFAPYRIDINEPERRIN H. LONG, M.D., W. BARRY WOOD JR., M.D.PERRIN H. LONG, M.D.Search for more papers by this author, W. BARRY WOOD JR., M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-13-3-487 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe rational utilization of any promising compound in the field of clinical chemotherapy is dependent upon a knowledge of its absorption by, distribution in, and excretion from the body. Early in the course of our studies upon sulfapyridine, we1noted that the drug was not readily soluble, and in comparison with sulfanilamide, poorly absorbed, when it was administered to animals by the oral route. While increasing doses gave blood levels of increasing amounts, these concentrations were not at all proportional to the dose, and certain individual animals showed marked variations from time to time in their ability to absorb the...Bibliography1. LONGFEINSTONE PHWH: Observations upon the absorption and excretion of sulfapyridine, Proc. Soc. Exper. Biol. and Med., 1938, xxxix, 486. CrossrefGoogle Scholar2. MARSHALLBRATTONLITCHFIELD EKACJT: The toxicity and absorption of 2-sulfanilamidopyridine and its soluble salt, Science, 1938, lxxxviii, 597. CrossrefGoogle Scholar3. BAINESWIEN EJR: The absorption and excretion of 2-sulphanilylaminopyridine, Quart. Jr. Pharm. and Pharmacol., 1939, xii, 4. Google Scholar4. BRATTONMARSHALL ACEK: A new coupling compound for sulfanilamide determination, Jr. Biol. Chem., 1939, cxxviii, 537. CrossrefGoogle Scholar5. ANTOPOLROBINSON WH: Urolithiasis and renal pathology after oral administration of 2 (sulfanilylamino)-pyridine (sulfapyridine), Proc. Soc. Exper. Biol. and Med., 1939, xl, 428. CrossrefGoogle Scholar6. GROSSCOOPERLEWIS PFBML: Urinary concretions caused by sulfapyridine, Proc. Soc. Exper. Biol. and Med., 1939, xl, 448. CrossrefGoogle Scholar7. LONGBLISS PHEA: The clinical and experimental use of sulfanilamide, sulfapyridine and allied compounds, 1939, Macmillan Company, New York City. Google Scholar8. MARSHALLLONG EKPH: The intravenous use of sodium sulfapyridine, Jr. Am. Med. Assoc, 1939, cxii, 1671. CrossrefGoogle Scholar9. HOBSONMACQUAIDE FGDH: Treatment of meningococcal meningitis with 2-sulphanilylamidopyridine (M. & B. 693), Lancet, 1938, ii, 1213. CrossrefGoogle Scholar10. SCHMIDTHUGHES LHHB: Absorption and excretion of sulfanilamidopyridine (2-para-aminobenzene-sulphonamidopyridine), Proc. Soc. Exper. Biol. and Med., 1939, xl, 409. CrossrefGoogle Scholar11. EVANSGAISFORD GMWF: Treatment of pneumonia with 2(p-aminobenzenesulphonamido) pyridine, Lancet, 1938, ii, 14. CrossrefGoogle Scholar12. TELLINGOLIVER MWA: Case of massive pneumonia, Type III with massive collapse, treated with 2(p-amino-benzenesulphonamide) pyridine, Lancet, 1938, i, 1391. CrossrefGoogle Scholar13. DYKEREID SCGC: Treatment of lobar pneumonia with M. & B. 693, Lancet, 1938, ii, 1157. CrossrefGoogle Scholar14. FLIPPINLOCKWOODPEPPERSCHWARTZ HFJSDSL: The treatment of pneumococcic pneumonia with sulfapyridine, Jr. Am. Med. Assoc., 1939, cxii, 529. CrossrefGoogle Scholar15. AGRANATDREOSTIORDMAN ALAOD: Treatment of pneumonia with 2(p-aminobenzenesulphonamido) pyridine (M. & B. 693), Lancet, 1939, i, 309. CrossrefGoogle Scholar16. BARNETTHARTMANNPERLEYRUHOFF HLAFAMMB: The treatment of pneumococcic infections in infants and children with sulfapyridine, Jr. Am. Med. Assoc., 1939, cxii, 518. CrossrefGoogle Scholar17. MACCOLL WA: Clinical experience with sulfapyridine, Jr. Pediat., 1939, xiv, 277. CrossrefGoogle Scholar18. CRAWFORD JH: Pneumococcal pneumonia complicating pulmonary tuberculosis, treated with M. & B. 693, Brit. Med. Jr., 1939, i, 608. CrossrefGoogle Scholar19. HODESSTIFLERWALKERMCCARTYSHIRLEY HLWCEMRG: The use of sulfapyridine in primary pneumococcic pneumonia and in pneumococcic pneumonia associated with measles, Jr. Pediat., 1939, xiv, 417. CrossrefGoogle Scholar20. GRAHAMWARNERDAUPHINEEDICKSON DWPJARC: The treatment of pneumococcal pneumonia with dagenan (M. & B. 693), Canad. Med. Assoc. Jr., 1939, xl, 325. Google Scholar21. MEAKINSHANSON JCFR: The treatment of pneumococcic pneumonia with sulfapyridine, Canad. Med. Assoc. Jr., 1939, xl, 333. Google Scholar22. PLUMMERENSWORTH NH: Preliminary report of the use of sulfapyridine in the treatment of pneumonia, Bull. N. Y. Acad. Med., 1939, Second Series, xv, 241. Google Scholar23. ALSTED G: Type III pneumococcal pneumonia, Effect of M. & B. 693, Lancet, 1939, i, 869. CrossrefGoogle Scholar24. ALSTED G: Behandling Af Pneumonia Med Sulfanilylaminopyridin (M. & B. 693), Ugesk. f. laeger, 1939, Nr. xvi, 480. Google Scholar25. FINLANDSPRINGLOWELLBROWN MWCFCJW: Specific serotherapy and chemotherapy of the pneumococcus pneumonias, ANN. INT. MED., 1939, xii, 1816. Google Scholar26. LAWRENCE EA: Recent advances in the treatment of pneumonia, Washington Institute of Med., 1939, p. 45. Google Scholar27. SOUTHWORTHCOOKE HC: Hematuria, abdominal pain and nitrogen retention associated with sulfapyridine, Jr. Am. Med. Assoc., 1939, cxii, 1820. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Baltimore, Maryland*Received for publication July 1, 1939.From The Medical Clinic of The Johns Hopkins Hospital and The Department of Medicine, The Johns Hopkins University, Baltimore, Maryland.This investigation was supported by a grant from The Chemical Foundation, Inc., of New York City. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe Nature and Treatment of Pneumococcal PneumoniaDie PneumonienRENAL COMPLICATIONS OF SULPHAPYRIDINE THERAPYIntensive Treatment of Gonorrh a and Non-Specific Urethritis with SulphapyridineThe Treatment of Pulmonary Infections with Sulfanilamide, Sulfapyridine, and SulfathiazoleAcute hemolytic anemia developing during therapy with substances belonging to the sulphanilamide groupLiteraturverzeichnisThe Occurrence of Urologic Complications in Humans Following Sulfapyridine Therapy 1 September 1939Volume 13, Issue 3Page: 487-512KeywordsAttentionBloodChemotherapyDrugsExcretionHospital medicinePatientsPneumoniaSodium ePublished: 1 December 2008 Issue Published: 1 September 1939 PDF downloadLoading ...